Skip to main content
. Author manuscript; available in PMC: 2017 Feb 22.
Published in final edited form as: Mol Cancer Ther. 2016 Apr 5;15(6):1412–1424. doi: 10.1158/1535-7163.MCT-15-0815

Figure 2.

Figure 2

Venn diagrams showing the overlap in plasma metabolites between preclinical animal models: (A) PTEN +/- (depleted) versus wild-type littermates and athymic mice bearing PTEN null human PC3 prostate carcinoma or U87MG glioblastoma xenografts compared with non-tumor bearing age-matched controls; (B) treatment with pictilisib versus vehicle in PC3- and U87MG-bearing mice; and (C) overlap between changes in all 3 models in (A) and those common to both models in (B). Metabolites that were further evaluated in the clinical setting are enclosed by a thick black line. (Tx: treatment)